SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)
Stock Information for SCYNEXIS Inc.
Loading
Please wait while we load your information from QuoteMedia.